Why 1 in 10 People May Be Genetically Resistant to GLP-1 Drugs Like Ozempic

For millions of people taking GLP-1 medications like Ozempic and Wegovy, these drugs have been life-changing. But if you're among the roughly 1 in 10 people who don't see the same dramatic results, new research from Stanford Medicine offers a compelling explanation: you might be genetically resistant to these medications.

The Discovery of GLP-1 Resistance

Stanford Medicine scientists and their international collaborators found that more than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the drugs might not work as well for people who have certain genetic variants. The genetic variants, carried by roughly 10% of the general population, cause a surprising phenomenon called GLP-1 resistance.

What makes this finding so puzzling is the paradox at its heart: people with these variants have higher levels of the hormone GLP-1, which helps regulate blood sugar, but the hormone is less biologically effective. It's like having a louder megaphone that somehow produces quieter sound.

"When I treat people in the diabetes clinic, I see a huge variation in response to these GLP-1-based medications and it is difficult to predict this response clinically," said study lead author Mahesh Umapathysivam, an endocrinologist at Adelaide University. "This is the first step in being able to use someone's genetic make-up to help us improve that decision-making process."

The Science Behind the Resistance

The researchers focused on variants in a gene that produces an enzyme called PAM (peptidyl-glycine alpha-amidating monooxygenase). This enzyme is uniquely capable of activating many hormones in the body, including GLP-1, through a process called amidation that increases the half-life or potency of biologically active peptides.

For the unlucky 10 percent with one of the two defective variants, the amidation process is stalled, and the carriers show higher rates of diabetes. When researchers gave healthy adults with and without these variants a sugary drink and measured their blood response, they found a striking pattern.

"Despite people with the PAM variant having higher circulating levels of GLP-1, we saw no evidence of higher biological activity. They were not reducing their blood sugar levels more quickly. More GLP-1 was needed to have the same biological effect, meaning they were resistant to GLP-1," explained study senior author Anna Gloyn from Stanford University.

Clinical Trial Data Reveals Real-World Impact

To see how this translated to actual treatment outcomes, researchers analyzed data from several clinical trials involving people with diabetes taking GLP-1 medications. In a combined analysis of three trials with 1,119 participants, individuals with PAM variants responded less effectively to GLP-1 drugs. After six months of treatment, about 25% of participants without the variants met the recommended HbA1c target, compared with 11.5% of those with the p.S539W variant and 18.5% of those with the p.D563G variant.

Importantly, these genetic variants did not affect how people responded to other common diabetes medications, including sulfonylureas, metformin and DPP-4i. "What was really striking was that we saw no effect from whether you have a variant on your response to other types of diabetes medications," Gloyn said.

This specificity suggests that if you're not responding well to semaglutide or other GLP-1 medications, you might still find success with different types of diabetes treatments.

The Weight Loss Question Remains Unclear

While the study focused on blood sugar regulation, it's not clear whether the variants affect weight loss from these drugs, such as Ozempic and Wegovy, which are increasingly prescribed to treat obesity. They are typically taken at higher doses for weight loss than for diabetes.

Only two of the clinical trials analyzed provided weight data, which showed no difference in weight loss between those with and without PAM variants, but the data is too limited to be conclusive, researchers noted. This leaves an important question unanswered for the millions using these medications primarily for weight management.

"This aligns with my clinical experience, where I frequently see a variable response to GLP-1 medications," said Dr. Mir Ali, a bariatric surgeon at MemorialCare Surgical Weight Loss Center, who wasn't involved in the study.

The uncertainty around weight loss effects means that if you're using tirzepatide or other GLP-1 medications for obesity, having these genetic variants doesn't necessarily predict your response. More research is needed to understand how genetics affects weight loss outcomes.

What This Means for You

If you're not seeing the results you expected from your GLP-1 medication, genetics might be part of the explanation. While genetic testing for GLP-1 resistance isn't yet available for routine clinical use, this research opens important doors for the future of personalized obesity treatment.

"There are a whole class of medications that are insulin sensitizers, so perhaps we can develop medications that will allow people to be sensitized to GLP-1s or find formulations of GLP-1, like the longer-acting versions, that avoid the GLP-1 resistance," Gloyn suggested.

For now, if you're not responding well to your current GLP-1 medication, work with your healthcare provider to explore other options. This might include trying different GLP-1 medications at various dosages, or considering alternative treatment approaches. You can find qualified providers through our clinic directory to discuss your personalized treatment options.

Don't let a poor initial response discourage you. Understanding that genetics play a role can be empowering—it means your experience isn't due to lack of willpower or commitment, but rather biological factors beyond your control.

The Future of Personalized Medicine

As one expert noted, "The broader lesson from recent research is that obesity treatment is entering a precision-medicine era." This Stanford study represents an important step toward understanding why one-size-fits-all approaches don't work for everyone, and why personalized treatment strategies will become increasingly important.

The research also highlights the need for better tools to predict who will respond to specific medications before starting treatment. In the future, genetic testing might help doctors choose the most effective medication for each individual, potentially saving time, money, and frustration.

For the 90% of people without these variants, this research reinforces that GLP-1 medications can be highly effective tools for managing diabetes and weight. For the 10% with genetic resistance, it validates their experience and points toward the need for alternative approaches and continued research into overcoming this resistance.

Sources

1. Stanford Medicine - One in 10 people may have resistance to GLP-1 diabetes drugs
2. ScienceDaily - Why Ozempic doesn't work for everyone: Scientists found a hidden reason
3. Healthline - Ozempic, Wegovy: Why GLP-1 Drugs Don't Work for Everyone
4. Genome Medicine - Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists